News Release

FDHT PET imaging of androgen receptors detects prostate cancer

Peer-Reviewed Publication

Society of Nuclear Medicine and Molecular Imaging

A recent study has revealed that FDHT-PET scanning of androgen receptors (AR) is successful in imaging patients with prostate cancer. Prostate cancer is one of the most common forms of cancer in American men, with more than 230,000 cases diagnosed each year. Researchers around the world are seeking better ways to detect and analyze this disease, and this research conducted by Farrokh Dehdashti, MD and colleagues from Mallinckrodt Institute of Radiology of Washington University School of Medicine in St. Louis, Missouri and the Department of Chemistry at the University of Illinois adds to the accumulated body of knowledge.

The study involved 15 men between the ages of 56 and 79 with advanced metastatic prostate cancer confirmed by biopsies or radiological studies. PET scans were performed using 16b-[18F] fluoro-5a-dihydrotestosterone (FDHT), a radiopharmaceutical specially designed for AR imaging. FDHT-PET findings were compared to bone scintigraphy and CT scan results, with abnormal FDHT uptake noted in the lesions of 10 patients.

FDHT-PET revealed numerous lesions in two patients; one patient had multiple osseous lesions (confirmed by bone scintigraphy), indicating the cancer had spread to the bones, while the other had extensive lymph node lesions (confirmed by CT). In the remaining 8 patients, FDHT-PET detected 10 of 16 osseous lesions identified by bone scintigraphy and all 9 lymph node metastases seen on CT scans. FDHT-PET also found 7 additional lymph node lesions in two patients and unsuspected lymph node lesions in one patient.

To assess whether FDHT is androgen receptor mediated, patients who had shown abnormal FDHT uptake were re-examined with FDHT-PET after a day of flutamide (an androgen-receptor antagonist) therapy. The average AR standardized uptake value (SUV) decreased significantly, as did the tumor-to-muscle ratio of identified lesions.

Dehdashti and her colleagues are encouraged by the evidence that FDHT-PET shows utility in evaluating prostate cancer patients. And, as Dehdashti stated, “We believe FDHT-PET may hold promise in assessing androgen receptor status of prostate cancer and may help to predict response to hormone therapy in prostate cancer patients. Future studies should be conducted in order to assess this capability.”

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.